U.S. markets open in 1 hour 25 minutes
  • S&P Futures

    4,585.00
    +13.75 (+0.30%)
     
  • Dow Futures

    35,332.00
    +73.00 (+0.21%)
     
  • Nasdaq Futures

    15,267.50
    +61.50 (+0.40%)
     
  • Russell 2000 Futures

    2,099.40
    +7.30 (+0.35%)
     
  • Crude Oil

    86.08
    +0.65 (+0.76%)
     
  • Gold

    1,817.20
    +4.80 (+0.26%)
     
  • Silver

    23.75
    +0.26 (+1.12%)
     
  • EUR/USD

    1.1343
    +0.0013 (+0.11%)
     
  • 10-Yr Bond

    1.8650
    0.0000 (0.00%)
     
  • Vix

    22.22
    +3.03 (+15.79%)
     
  • GBP/USD

    1.3637
    +0.0039 (+0.28%)
     
  • USD/JPY

    114.4900
    -0.0950 (-0.08%)
     
  • BTC-USD

    42,161.36
    +362.43 (+0.87%)
     
  • CMC Crypto 200

    999.29
    -10.09 (-1.00%)
     
  • FTSE 100

    7,597.78
    +34.23 (+0.45%)
     
  • Nikkei 225

    27,467.23
    -790.02 (-2.80%)
     

Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it will present results from a preclinical study of a research form of KER-012 (“RKER-012”) at the American Heart Association (“AHA”) 2021 Scientific Sessions, to be held virtually from November 13 through 15, 2021.

The following abstract was posted to the AHA website on November 8, 2021, 5:00 a.m. Eastern time.

Preclinical Presentation

“KER-012, a Novel Modified ActRII Ligand Trap, Attenuated Cardiac Pathology in a Pulmonary Arterial Banding Model of Right Ventricle Overload”

  • Presentation Number: 278

  • Session Name: Novel Targets in Pulmonary Hypertension and RV Failure: Epigenetics, Development, and Hypertrophy

  • Date: Saturday, November 13, 2021

  • Abstract Number: 11209

About KER-012

KER-012 is designed to bind to and inhibit the transforming growth factor-Beta ligands that suppress bone growth, including activin A and activin B, in order to promote bone growth to potentially treat diseases such as osteogenesis imperfecta and osteoporosis. Keros believes that KER-012 has the potential to increase the signaling of bone morphogenic protein (“BMP”) pathways through this inhibition of activin A and activin B signaling, and consequently treat diseases such as PAH that are associated with reduced BMP signaling due to inactivating mutations in the BMP receptors. KER-012 is being developed for the treatment of disorders associated with bone loss, such as osteogenesis imperfecta and osteoporosis, and for the treatment of PAH.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of PAH.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “would” and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ presentation plans for the upcoming AHA Scientific Sessions. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its lead product candidates, KER-050 and KER-047; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; Keros’ dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; Keros’ ability to enter into new collaborations; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 4, 2021, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Mike Biega
mbiega@soleburytrout.com
(617) 221-9660